What the labels say about urine and kidneys
Mounjaro® is a weekly tirzepatide injection for type 2 diabetes [1]. None of its labels lists frequent urination, urgency or night-time urination, in the US tables or postmarketing list, the European table of adverse reactions or the Canadian monograph [1][3][4].
What the labels do discuss is acute kidney injury after fluid loss. The US label reports postmarketing cases, some needing dialysis, mostly in people who had become dehydrated after nausea, vomiting or diarrhea, and advises checking kidney function in people with such reactions, especially when starting or raising the dose [1]. The Canadian patient information lists dark yellow, strong-smelling urine, extreme thirst and dizziness as signs of that dehydration [4], and MedlinePlus lists passing less urine among its signs [11].
On how tirzepatide leaves the body, the US label says its breakdown products are excreted in urine and stool, and intact tirzepatide is not found in either [1]. Nothing in the label suggests that the medicine itself acts as a diuretic.
| Source | Frequent urination | Urine-related warning |
|---|---|---|
| US label and Medication Guide, 08/2026 | Not listed [1][2] | Acute kidney injury after dehydration [1][2] |
| EU product information | Not listed [3] | Risk of dehydration and declining kidney function [3] |
| Canadian monograph, 06/2026 | Not listed [4] | Dark yellow, strong-smelling urine as a dehydration sign [4] |
Kidney findings from tirzepatide trials
Two large analyses looked at kidney outcomes rather than urination. A post hoc analysis of SURPASS-4, in 2,002 adults with type 2 diabetes and high cardiovascular risk, found that kidney function (eGFR) declined more slowly on tirzepatide than on insulin glargine, and protein in the urine did not rise on tirzepatide while it did on insulin [5]. The composite kidney outcome was less frequent with tirzepatide (hazard ratio 0.58).
A pre-specified exploratory analysis of SURPASS-CVOT, in 13,165 adults with type 2 diabetes and heart or vessel disease, found a 23% lower risk of major kidney events with tirzepatide than with dulaglutide over about four years, driven by less new heavy protein in the urine and slower decline in kidney function in those at higher risk [6]. Nausea, vomiting and diarrhea were more common on tirzepatide [6].
Neither analysis measured how often people urinated, and neither replaces the label’s warning about dehydration.
Why you might be going more often
High blood sugar: MedlinePlus lists needing to urinate a lot, or getting up more often at night to urinate, together with thirst and a dry mouth, among the symptoms of high blood sugar [8]. Poorly controlled diabetes is also on its list of causes of frequent urination [7]. Mounjaro® lowers fasting and after-meal glucose [1], so sugar-driven urination may ease as control improves, though no study has measured this for Mounjaro®.
Other diabetes tablets: empagliflozin, an SGLT2 inhibitor, lowers blood sugar by making the kidneys pass more glucose into the urine, and MedlinePlus lists urinating a lot, including at night, among its side effects [9]. In SURPASS-CVOT, 31% of participants were taking an SGLT2 inhibitor at the start [1].
Drinking more: the Medication Guide encourages fluids to reduce the chance of dehydration [2], and more fluid in naturally means more trips. Caffeine and alcohol add to this [7].
Infection: a urinary tract infection causes an urge to urinate often, burning, cloudy or reddish urine and sometimes fever or back pain [10].
Other causes to keep in mind
MedlinePlus lists an enlarged prostate in middle-aged and older men, inflammation of the urethra, vaginitis, overactive bladder, nerve problems, anxiety, diuretics (water pills), pregnancy, interstitial cystitis, pelvic radiation and, rarely, bladder cancer or a pelvic growth [7]. Strokes and other nervous system diseases can also affect bladder control [7].
Most people sleep six to eight hours without needing to urinate, according to MedlinePlus [7]. Getting up repeatedly at night is called nocturia and is worth mentioning at your next appointment, especially if it is new.
Practical steps
MedlinePlus suggests keeping a voiding diary, noting when you urinate and roughly how much, and taking it to your appointment [7]. For night-time urination it advises not drinking large amounts close to bedtime and cutting down on alcohol and caffeine [7].
Do not cut back on fluids during the day to reduce trips: the Mounjaro® labels stress staying hydrated, particularly when nausea, vomiting or diarrhea are present [2][3]. If you check your blood sugar, a reading taken when you notice increased thirst and urination shows whether high glucose is involved [8].
Do not stop or change Mounjaro® or an SGLT2 inhibitor without talking to your prescriber.
Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Passing very little or no urine, or very dark amber urine, with confusion, dizziness or a racing heart
Contact: Emergency services
MedlinePlus [11]
Today
- Urinary symptoms with fever, back or side pain, vomiting or shaking chills
Contact: Your clinician right away
- Peeing a lot with strong thirst, unexplained weight loss or high readings, or ketones in the urine
Contact: Your diabetes team; with ketones, your provider or emergency care
- Burning or pain when you pee, or cloudy, reddish or bad-smelling urine
Contact: Your clinician
MedlinePlus [10]
At your next appointment
- Frequent urination without drinking more, new leaks or blood in the urine
Contact: Your clinician
MedlinePlus [7]